Plenary programme

A new era in atherothrombosis
Lina Badimon, Spain

Vascular aging from biology to the clinic
Konstantinos Stellos, Germany

Y Chromosome Loss and CHIP in ASCVD
José Fuster, Spain

AI-enhanced exposomics in CV health
Rajagopalan Sanjay, USA

Structure of “bad” lipoproteins
Alan Remaley, USA

Novel therapies for remnant cholesterol & TGs
Robert Rosenson, USA

Exercise and cardiovascular disease
Hendrik Sager, Germany

Atherosclerosis and dementia – causal aspects and preventive potential
Ruth Frikke-Schmidt, Denmark

Precision medicine for CV prevention
Joseph Loscalzo Brigham, USA

Can CT alone guide ASCVD therapy?
Charalambos Antoniades, UK

Can markers predict plaque vulnerability?
Isabel Goncalves, Sweden

The PCSK family in CVD and beyond
Nabil Seidah, Canada